US FDA’s ‘Plausible Mechanism’ Pathway: A Platform-Based Approach Not Just For Rare Diseases

 
• By Sue Sutter
  
New pathway
FDA is building a new plausible mechanism approval pathway. (Shutterstock)

More from Review Pathways

More from United States